• The new systems for early access are expected to expand the existing opportunities for investigational drugs for only a limited part of the patients.
CONCLUSIONS
A documentary research was conducted by analyzing government documents and the Diet Record.
METHOD
As a result of the documentary search, three systems were identified to serve for the aim of early access in Japan: Advanced Medical Care B (AMC-B) 1) , Patient-Initiated Mixed-Care system (PIMC) 2) , Compassionate Use (CU) 3) system. Each system is described in detail below.
RESULTS
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OBJECTIVE RESULTS (CONT'D)
• The Patient-Initiated Mixed-Care system (PIMC) is planned to start in 2016.
• Patients and the attending doctors consult Core Clinical Research Hospitals to find an opportunity to use an investigational treatment.
• A (In figure 2) : When a clinical trial/CU is ongoing, patients are expected to participate in it.
• B: If no clinical trial/CU is ongoing, they have an option to develop a PIMC clinical research and ask for the use of the unapproved/off-label drug. The plan has to be made aiming at reimbursement in medical insurance.
• C: Once a PIMC clinical research is endorsed, new cases can be started after an approval by each Core Clinical Research Hospitals.
• No financial aid is in place for the investigational treatment. Although the cost of the other treatments for the patient are reimbursed, many patients may not be able to afford to use PIMC system.
• The Compassionate Use (CU or Expanded Clinical Trial) system is to be fully introduced in 2016 and targets medicines at later stages of clinical development, opening up opportunities for patients who are not eligible for the clinical trials.
• A (In figure 3) : Basically, doctors ask pharmaceutical companies for the use of investigational drugs. Unlike AMC-B or PIMC, CU will be always conducted as a clinical trial, complying with GCP.
• B: When the pharmaceutical company does not offer a compassionate use for the patients, the doctors can request the review conference for re-evaluation. The company will be asked to make the final decision.
• C: CU can also be implemented as a doctor-led trial.
• The treatment cost of the investigational drug will be paid by either patients or the investigators. In most cases of clinical trials, the cost is paid by the investigators.
The three systems are compared in Table 1 to highlight the major differences
• The present form of Advanced Medical Care (AMC) started in 2012. AMC consists of AMC-A and AMC-B. AMC-A is for approved technologies and unapproved drugs are not made available under this system. AMC-B is for unapproved/off-label drugs.
• Researchers at Health Insurance-Covered Medical Institution plan a clinical study to evaluate the unapproved/ off-label technologies and apply to the review board (Committee for Advanced Medical Care).
• The review board designates technologies that include the use of unapproved medicines or off-label indications, after requests from researchers.
• The cost of unapproved/off-label drug is not reimbursed in AMC-B system, but in many cases part of the cost is paid by involving companies or with research budget. The cost of the concomitant approved treatments are reimbursed.
Advanced Medical Care B (AMC-B)
Comparison
Position of each system
Patient-Initiated Mixed-Care system (PIMC)
• The three systems are complementary, in that they are targeting different drugs and population, with PIMC rescuing those excluded from the other two systems.
• Under PIMC, more patients will be able to access to unapproved/investigational drugs more easily. However, the target drugs will be listed by medical experts and other new drugs will be kept unaccessible. This will prevent potential drug-related health disater and keep mixed care restricted as before.
Japanese version of Compassionate Use system (CU)
